Tat-calpastatin fusion proteins transduce primary rat cortical neurons but do not inhibit cellular calpain activity

Experimental Neurology

Volumn 188, Issue 1, 2004, Pages 161-170

  Sengoku, Tomoko ^a   Bondada, Vimala ^a   Hassane, Duane ^a   Dubal, Sam ^a   Geddes, James W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cysteine proteases; Endosomes; Protein transduction; Spectrin

Indexed keywords

CALPAIN; CALPASTATIN; HYBRID PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TRANSPORT; ENDOSOME; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS; HUMAN IMMUNODEFICIENCY VIRUS; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; STRUCTURE ANALYSIS;

ANIMALS; BRAIN DISEASES; CALCIUM-BINDING PROTEINS; CALPAIN; CELL COMPARTMENTATION; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSOMES; FETUS; GENE PRODUCTS, TAT; HUMANS; NERVE DEGENERATION; NEURONS; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

EID: 2942613324     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.03.018     Document Type: Article

References (81)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 298:2002;846-850
2. Adamec E., Mohan P., Vonsattel J.P., Nixon R.A. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol. (Berl.). 104:2002;92-104
3. Anderson G.J., Powell L.W., Halliday J.W. The endocytosis of transferrin by rat intestinal epithelial cells. Gastroenterology. 106:1994;414-422
4. Ariyoshi H., Shiba E., Sakon M., Kambayashi J., Yoshida K., Kawashima S., Mori T. Translocation of human platelet calpain-I. Biochem. Mol. Biol. Int. 30:1993;63-72
5. Asoh S., Ohsawa I., Mori T., Katsura K., Hiraide T., Katayama Y., Kimura M., Ozaki D., Yamagata K., Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A. 99:2002;17107-17112
6. Bartus R.T., Baker K.L., Heiser A.D., Sawyer S.D., Dean R.L., Elliott P.J., Straub J.A. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J. Cereb. Blood Flow Metab. 14:1994;537-544
7. Baudry M., DuBrin R., Lynch G. Subcellular compartmentalization of calcium-dependent and calcium-independent neutral proteases in brain. Synapse. 1:1987;506-511
8. Becker-Hapak M., McAllister S.S., Dowdy S.F. TAT-mediated protein transduction into mammalian cells. Methods. 24:2001;247-256
9. Brewer G.J., Torricelli J.R., Evege E.K., Price P.J. Optimized survival of hippocampal neurons in B27-supplemented neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35:1993;567-576
10. Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., Lu A., Ran R., Graham S.H., Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:2002;5423-5431
11. Chakrabarti A.K., Banik N.L., Powers J.M., Hogan E.L. The regional and subcellular distribution of calcium activated neutral proteinase (CANP) in the bovine central nervous system. Neurochem. Res. 14:1989;259-266
12. Chakrabarti A.K., Neuberger T., Russell T., Banik N.L., DeVries G.H. Immunolocalization of cytoplasmic and myelin mcalpain in transfected Schwann cells: II. Effect of withdrawal of growth factors. J. Neurosci. Res. 47:1997;609-616
13. Croall D.E., DeMartino G.N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71:1991;813-847
14. De Tullio R., Passalacqua M., Averna M., Salamino F., Melloni E., Pontremoli S. Changes in intracellular localization of calpastatin during calpain activation. Biochem. J. 343(Pt. 2):1999;467-472
15. Dietz G.P., Kilic E., Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol. Cell. Neurosci. 21:2002;29-37
16. Di Rosa G., Odrijin T., Nixon R.A., Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J. Mol. Neurosci. 19:2002;135-141
17. Donkor I.O. A survey of calpain inhibitors. Curr. Med. Chem. 7:2000;1171-1188
18. Egleton R.D., Davis T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides. 18:1997;1431-1439
19. Emori Y., Kawasaki H., Imajoh S., Minami Y., Suzuki K. All four repeating domains of the endogenous inhibitor for calcium-dependent protease independently retain inhibitory activity. Expression of the cDNA fragments in Escherichia coli. J. Biol. Chem. 263:1988;2364-2370
20. Fischer R., Kohler K., Fotin-Mleczek M., Brock R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279:2004;12625-12635
21. Ford K.G., Souberbielle B.E., Darling D., Farzaneh F. Protein transduction: an alternative to genetic intervention? Gene Ther. 8:2001;1-4
22. Futaki S., Goto S., Suzuki T., Nakase I., Sugiura Y. Structural variety of membrane permeable peptides. Curr. Protein Pept. Sci. 4:2003;87-96
23. Gafni J., Ellerby L.M. Calpain activation in Huntington's disease. J. Neurosci. 22:2002;4842-4849
24. Gil-Parrado S., Assfalg-Machleidt I., Fiorino F., Deluca D., Pfeiler D., Schaschke N., Moroder L., Machleidt W. Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin. Biol. Chem. 384:2003;395-402
25. Goll D.E., Thompson V.F., Li H., Wei W., Cong J. The calpain system. Physiol. Rev. 83:2003;731-801
26. Hitomi K., Yokoyama A., Maki M. Expression of biologically active human calpastatin in baculovirus-infected insect cells and in Escherichia coli. Biosci., Biotechnol., Biochem. 62:1998;136-141
27. Hood J.L., Logan B.B., Sinai A.P., Brooks W.H., Roszman T.L. Association of the calpain/calpastatin network with subcellular organelles. Biochem. Biophys. Res. Commun. 310:2003;1200-1212
28. Huang Y., Wang K.K. The calpain family and human disease. Trends Mol. Med. 7:2001;355-362
29. Kilic U., Kilic E., Dietz G.P., Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke. 34:2003;1304-1310
30. Kim Y.J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K.B., Qin Z.H., Aronin N., DiFiglia M. Caspase 3-cleaved N-terminal fragments of wild-type and mutant Huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12784-12789
31. Kim S.J., Sung J.Y., Um J.W., Hattori N., Mizuno Y., Tanaka K., Paik S.R., Kim J., Chung K.C. Parkin cleaves intracellular alpha-synuclein's inclusions via the activation of calpain. J. Biol. Chem. 278:2003;41890-41899
32. Kupina N.C., Nath R., Bernath E.E., Inoue J., Mitsuyoshi A., Yuen P.W., Wang K.K., Hall E.D. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J. Neurotrauma. 18:2001;1229-1240
33. Kwon H.Y., Eum W.S., Jang H.W., Kang J.H., Ryu J., Ryong Lee B., Jin L.H., Park J., Choi S.Y. Transduction of Cu, Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett. 485:2000;163-167
34. Lundberg M., Johansson M. Is VP22 nuclear homing an artifact? Nat. Biotechnol. 19:2001;713
35. Maki M., Takano E., Mori H., Sato A., Murachi T., Hatanaka M. All four internally repetitive domains of pig calpastatin possess inhibitory activities against calpains I and II. FEBS Lett. 223:1987;174-180
36. Maki M., Bagci H., Hamaguchi K., Ueda M., Murachi T., Hatanaka M. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J. Biol. Chem. 264:1989;18866-18869
37. Maki M., Ma H., Takano E., Adachi Y., Lee W.J., Hatanaka M., Murachi T. Calpastatins: biochemical and molecular biological studies. Biomed. Biochim. Acta. 50:1991;509-516
38. Markgraf C.G., Velayo N.L., Johnson M.P., McCarty D.R., Medhi S., Koehl J.R., Chmielewski P.A., Linnik M.D. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke. 29:1998;152-158
39. Mehdi S. Cell-penetrating inhibitors of calpain. Trends Biochem. Sci. 16:1991;150-153
40. Mellgren R.L. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome. J. Biol. Chem. 272:1997;29899-29903
41. Melloni E., De Tullio R., Averna M., Tedesco I., Salamino F., Sparatore B., Pontremoli S. Properties of calpastatin forms in rat brain. FEBS Lett. 431:1998;55-58
42. Minger S.L., Geddes J.W., Holtz M.L., Craddock S.D., Whiteheart S.W., Siman R.G., Pettigrew L.C. Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia. Brain Res. 810:1998;181-199
43. Mishizen-Eberz A.J., Guttmann R.P., Giasson B.I., Day G.A. III, Hodara R., Ischiropoulos H., Lee V.M., Trojanowski J.Q., Lynch D.R. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86:2003;836-847
44. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., Becker-Hapak M., Ezhevsky S.A., Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4:1998;1449-1452
45. Namiki S., Tomida T., Tanabe M., Iino M., Hirose K. Intracellular delivery of glutathione S-transferase into mammalian cells. Biochem. Biophys. Res. Commun. 305:2003;592-597
46. Nath A., Psooy K., Martin C., Knudsen B., Magnuson D.S., Haughey N., Geiger J.D. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70:1996;1475-1480
47. Newcomb J.K., Kampfl A., Posmantur R.M., Zhao X., Pike B.R., Liu S.J., Clifton G.L., Hayes R.L. Immunohistochemical study of calpain-mediated breakdown products to alpha-spectrin following controlled cortical impact injury in the rat. J. Neurotrauma. 14:1997;369-383
48. Nixon R.A., Saito K.I., Grynspan F., Griffin W.R., Katayama S., Honda T., Mohan P.S., Shea T.B., Beermann M. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann. N. Y. Acad. Sci. 747:1994;77-91
49. Ono Y., Sorimachi H., Suzuk K. The calpain superfamily. Wang K.K.W., Yuen P.-W. Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease. 1999;1-23 Taylor and Francis, Philadelphia
50. Perlmutter L.S., Siman R., Gall C., Seubert P., Baudry M., Lynch G. The ultrastructural localization of calcium-activated protease "calpain" in rat brain. Synapse. 2:1988;79-88
51. Potocky T.B., Menon A.K., Gellman S.H. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a {beta}-peptide after endocytic uptake into HeLa cells. J. Biol. Chem. 278:2003;50188-50194
52. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54:2002;561-587
53. Ray S.K., Banik N.L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 2:2003;173-189
54. Ray S.K., Hogan E.L., Banik N.L. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res. Brain Res. Rev. 42:2003;169-185
55. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278:2003;585-590
56. Roberts-Lewis J.M., Savage M.J., Marcy V.R., Pinsker L.R., Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J. Neurosci. 14:1994;3934-3944
57. Saatman K.E., Bozyczko-Coyne D., Marcy V., Siman R., McIntosh T.K. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J. Neuropathol. Exp. Neurol. 55:1996;850-860
58. Saatman K.E., Zhang C., Bartus R.T., McIntosh T.K. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. J. Cereb. Blood Flow Metab. 20:2000;66-73
59. Saido T.C., Yokota M., Nagao S., Yamaura I., Tani E., Tsuchiya T., Suzuki K., Kawashima S. Spatial resolution of fodrin proteolysis in postischemic brain. J. Biol. Chem. 268:1993;25239-25243
60. Sato K., Saito Y., Kawashima S. Identification and characterization of membrane-bound calpains in clathrin-coated vesicles from bovine brain. Eur. J. Biochem. 230:1995;25-31
61. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1999;1569-1572
62. Schwarze S.R., Hruska K.A., Dowdy S.F. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10:2000;290-295
63. Siman R., Noszek J.C. Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron. 1:1988;279-287
64. Siman R., Noszek J.C., Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J. Neurosci. 9:1989;1579-1590
65. Springer J.E., Azbill R.D., Kennedy S.E., George J., Geddes J.W. Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: attenuation with riluzole pretreatment. J. Neurochem. 69:1997;1592-1600
66. Takano E., Hamakubo T., Kawatani Y., Ueda M., Kannagi R., Murachi T. Multiple forms of calpastatin in pig brain. Biochem. Int. 19:1989;633-643
67. Takano E., Ueda M., Tsunekawa S., Murakami T., Maki M., Hatanaka M., Murachi T. Molecular diversity of erythrocyte calpastatin. Biomed. Biochim. Acta. 50:1991;517-521
68. Takano J., Watanabe M., Hitomi K., Maki M. Four types of calpastatin isoforms with distinct amino-terminal sequences are specified by alternative first exons and differentially expressed in mouse tissues. J. Biochem. (Tokyo). 128:2000;83-92
69. Takeuchi K.H., Saito K.I., Nixon R.A. Immunoassay and activity of calcium-activated neutral proteinase (mCANP): distribution in soluble and membrane-associated fractions in human and mouse brain. J. Neurochem. 58:1992;1526-1532
70. Taylor R.G., Christiansen J.A., Goll D.E. Immunolocalization of the calpains and calpastatin in human and bovine platelets. Biomed. Biochim. Acta. 50:1991;491-498
71. Thompson V.F., Saldana S., Cong J., Goll D.E. A BODIPY fluorescent microplate assay for measuring activity of calpains and other proteases. Anal. Biochem. 279:2000;170-178
72. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targeting. 6:1998;151-165
73. Vazquez J., Sun C., Du J., Fuentes L., Sumners C., Raizada M.K. Transduction of a functional domain of the AT1 receptor in neurons by HIV-Tat PTD. Hypertension. 41:2003;751-756
74. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272:1997;16010-16017
75. Volbracht C., Fava E., Leist M., Nicotera P. Calpain inhibitors prevent nitric oxide-triggered excitotoxic apoptosis. NeuroReport. 12:2001;3645-3648
76. Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10:2004;310-315
77. Wang K.K.W. Calpain substrates, assay methods, regulation, and its inhibitory agents. Wang K.K.W., Yuen P.-W. Calpain: Pharmacology and Toxicology of Calcium-Dependent Protease. 1999;77-101 Taylor and Francis, Philadelphia, PA
78. Wang K.K. Calpain and caspase: can you tell the difference? Trends Neurosci. 23:2000;20-26
79. Wu H.Y., Tomizawa K., Matsushita M., Lu Y.F., Li S.T., Matsui H. Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain. Neurosci. Res. 47:2003;131-135
80. Xia H., Mao Q., Davidson B.L. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19:2001;640-644
81. Zhang S.X., Bondada V., Geddes J.W. Evaluation of conditions for calpain inhibition in the rat spinal cord: effective postinjury inhibition with intraspinal MDL28170 microinjection. J. Neurotrauma. 20:2003;59-67